Liraglutide (Saxenda®). HTA ID: 19039

Assessment Status Assessment process complete
HTA ID 19039
Drug Liraglutide
Brand Saxenda®
Indication As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The Applicant is seeking reimbursement in a subgroup of the licensed population, that is,  as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥35kg/m2 with pre-diabetes and high risk of cardiovascular disease.
Assessment Process
Rapid review commissioned 18/09/2019
Rapid review completed 24/10/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of liraglutide (Saxenda®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/10/2019
Pre-submission consultation with Applicant 12/11/2019
Full submission received from Applicant 08/06/2020
Preliminary review sent to Applicant 21/08/2020
NCPE assessment re-commenced 23/10/2020
Follow-up to preliminary review sent to Applicant 30/11/2020
NCPE assessment re-commenced 08/12/2020
Factual accuracy sent to Applicant 15/01/2021
NCPE assessment re-commenced 22/01/2021
NCPE assessment completed 09/02/2021
NCPE assessment outcome The NCPE recommends that liraglutide 3mg (Saxenda®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary

The HSE has approved reimbursement following confidential price negotiations January 2023.